Two Sigma Advisers
RNTX

Two Sigma Advisers’s Rein Therapeutics RNTX Stock Holding History

Two Sigma Advisers’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-565
Closed -$6K – 2940
2021
Q4 		$6K Buy
+565
New +$8.74K ﹤0.01% 2586
2021
Q3 		– Sell
-6,240
Closed -$156K – 2719
2021
Q2 		$156K Sell
6,240
-2,980
-32% -$74.3K ﹤0.01% 2298
2021
Q1 		$264K Buy
+9,220
New +$316K ﹤0.01% 2273

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCA
Taconic Capital Advisors New York $229M AUM 110.07% 1-Year Est. Return

Two Sigma Advisers's RNTX Position: Q1 2022 in Review

Two Sigma Advisers sold out of Rein Therapeutics (RNTX) in Q1 2022, closing a stake of 565 shares — an estimated $6K sold.

Two Sigma Advisers first reported a position in RNTX in Q1 2021 and held it in 3 quarters. The position peaked at $264K in Q1 2021. 42 funds tracked by Wall St. Rank hold RNTX as of Q1 2022.

  • Two Sigma Advisers reported no remaining Rein Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Two Sigma Advisers sold 565 Rein Therapeutics shares in Q1 2022, an estimated $6K.
  • Two Sigma Advisers first reported a position in Rein Therapeutics in Q1 2021 and held it in 3 quarters.
  • Two Sigma Advisers's Rein Therapeutics position peaked at $264K in Q1 2021.
  • 42 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2022.

Based on Two Sigma Advisers's 13F filing for Q1 2022, filed 16 May 2022.